Skip to main content

Benitec Biopharma Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

BNTC$9.54+10.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

INDEX TO FORM 10-Q

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS1
PART I-FINANCIAL INFORMATION2
ITEM 1.Financial Statements2
Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and June 30, 20242
Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended September 30, 2024 and 2023 (Unaudited)3
Consolidated Statements of Stockholders’ Equity for the Three Months Ended September 30, 2024 and 2023 (Unaudited)4
Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2024 and 2023 (Unaudited)5
Notes to Consolidated Financial Statements (Unaudited)6
ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21
ITEM 3.Quantitative and Qualitative Disclosures About Market Risk52
ITEM 4.Controls and Procedures52
PART II-OTHER INFORMATION
ITEM 1.Legal Proceedings53
ITEM 1A.Risk Factors53
ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds53
ITEM 3.Defaults Upon Senior Securities53
ITEM 4.Mine Safety Disclosures53
ITEM 5.Other Information53
ITEM 6.Exhibits54
SIGNATURES55
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.